Published Date: 08 Mar 2023
This review compared the effectiveness of entecavir and tenofovir in reducing relapses and mortality after treatment for HBV-related hepatocellular carcinoma.
Read Full NewsFDA approves a label update for the BEAR implant, which was previously approved in 2020.
Physicians experience significant challenges with increasing administrative burdens impacting patient care. Study shows AI scribes can help reduce burnout.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 23, 2026.
Jerel Banks, MD, PhD, chief executive officer of Benitec Biopharma, reviews early phase 1b/2a clinical signals, mechanism, and next steps for BB-301 in oculopharyngeal muscular dystrophy.
Benitec Biopharma reveals promising results for BB-301, a gene therapy showing significant improvements in swallowing function for OPMD patients.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ALS Treatment pathways!
GLP-1 Discontinuation Results in Significant Weight Regain, With Michael Weintraub, MD
1.
Hereditary cancer has a rare and underreported cause.
2.
When it comes to LBCL relapse in complete remission, ASCT outperforms CAR T-cell therapy.
3.
Large, Grade 4 Kidney Tumors Pose Risk of Early Cancer-Specific Mortality
4.
Exercise can counter detrimental effects of cancer treatment, review suggests
5.
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement
1.
Interpreting Iron Studies: What Your Blood Results Really Mean
2.
Exploring the Benefits of Endari: How This Natural Remedy Can Help You Live a Healthier Life
3.
Decoding the Future: Cancer Genomics and Radiomics in Oncology
4.
The Importance of Having a Quick and Effective Heparin Antidote
5.
The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
3.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation